Arbejdsmarkedets Tillaegspension Acquires Shares of 375,933 Halozyme Therapeutics, Inc. $HALO

Arbejdsmarkedets Tillaegspension acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 375,933 shares of the biopharmaceutical company’s stock, valued at approximately $25,300,000. Halozyme Therapeutics comprises 0.6% of Arbejdsmarkedets Tillaegspension’s holdings, making the stock its 3rd biggest holding.

A number of other large investors have also added to or reduced their stakes in the stock. DLD Asset Management LP raised its stake in Halozyme Therapeutics by 20.0% during the third quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock valued at $2,200,200,000 after buying an additional 5,000,000 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in Halozyme Therapeutics by 29.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock valued at $241,337,000 after buying an additional 749,484 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Halozyme Therapeutics by 3.2% during the third quarter. Dimensional Fund Advisors LP now owns 2,078,426 shares of the biopharmaceutical company’s stock valued at $152,431,000 after buying an additional 63,699 shares during the last quarter. Federated Hermes Inc. raised its stake in Halozyme Therapeutics by 294.1% during the third quarter. Federated Hermes Inc. now owns 1,450,704 shares of the biopharmaceutical company’s stock valued at $106,395,000 after buying an additional 1,082,638 shares during the last quarter. Finally, LSV Asset Management raised its stake in Halozyme Therapeutics by 0.9% during the third quarter. LSV Asset Management now owns 1,266,027 shares of the biopharmaceutical company’s stock valued at $92,850,000 after buying an additional 10,787 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the business’s stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $69.19, for a total transaction of $691,900.00. Following the completion of the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $53,122,698.20. The trade was a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 8,857 shares of the business’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $67.64, for a total value of $599,087.48. Following the sale, the chief operating officer directly owned 7,055 shares of the company’s stock, valued at $477,200.20. This represents a 55.66% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 120,482 shares of company stock valued at $8,200,842. Company insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Stock Down 1.2%

Halozyme Therapeutics stock opened at $69.21 on Friday. The stock has a market cap of $8.21 billion, a PE ratio of 24.90, a price-to-earnings-growth ratio of 0.29 and a beta of 0.89. The company has a debt-to-equity ratio of 8.81, a quick ratio of 3.66 and a current ratio of 2.76. Halozyme Therapeutics, Inc. has a one year low of $47.74 and a one year high of $82.22. The stock has a fifty day moving average of $65.70 and a 200 day moving average of $68.65.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The business had revenue of $376.71 million during the quarter, compared to analyst estimates of $358.60 million. During the same quarter in the previous year, the company posted $1.11 earnings per share. Halozyme Therapeutics’s revenue for the quarter was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 7.68 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Wells Fargo & Company lifted their price objective on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research note on Thursday, February 19th. HC Wainwright boosted their price target on Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday. Finally, Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Saturday, February 21st. Seven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $80.67.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.